Samsung Biologics
₩1,351,000.00Change from previous close: −4.82%Absolute change: −₩68,363.63
Financial data
Amounts in millions of KRW; per-share values in KRW; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | 4,556,972 | 3,497,146 | 3,694,589 | 3,001,295 | 1,568,007 |
| Cost of revenue | 2,056,131 | 1,798,093 | 1,900,080 | 1,540,526 | 844,657 |
| Gross profit | 2,500,841 | 1,699,053 | 1,794,509 | 1,460,769 | 723,350 |
| Selling, general and administrative | 357,259 | 313,046 | 535,421 | 380,456 | 169,630 |
| Research and development | 37,181 | 36,711 | 81,588 | 45,884 | 954 |
| Operating income | 2,069,221 | 1,321,366 | 1,113,680 | 983,627 | 537,309 |
| EBIT | 2,069,221 | 1,321,366 | 1,113,680 | 983,627 | 537,309 |
| EBITDA | 2,702,858 | 1,920,468 | 1,603,462 | 1,291,892 | 699,098 |
| Interest expense | 29,171 | 34,123 | 81,596 | 64,064 | 14,707 |
| Pre-tax income | 2,118,631 | 1,384,869 | 1,119,987 | 1,009,025 | 561,283 |
| Income tax | 504,301 | 344,567 | 262,296 | 210,968 | 167,693 |
| Net income | 1,784,352 | 1,083,316 | 857,691 | 798,056 | 393,589 |
| Net income to common shareholders | 1,784,352 | 1,083,316 | 857,691 | 798,056 | 393,589 |
| Basic EPS | 40,941.49 | 23,402.33 | 18,528.27 | 17,592.79 | 9,146.19 |
| Diluted EPS | 40,941.49 | 23,402.33 | 18,528.27 | 17,577.11 | 9,146.19 |
| Average shares (basic) | 43.6 | 46.3 | 46.3 | 45.4 | 43.0 |
| Average shares (diluted) | 43.6 | 46.3 | 46.3 | 45.4 | 43.0 |